


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

POSITIVE PROFIT ALERT AND INSIDE INFORMATION

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment on the unaudited management accounts of the Group for the six months ended 30 June 2021 and information currently available to the Board, it is expected the Group will record a profit attributable to the owners of the Company in the range of HK\$55 million to HK\$65 million for the six months ended 30 June 2021 as compared to the loss attributable to the owners of the Company in the amount of approximately HK\$6 million for the six months ended 30 June 2020.

Based on the information currently available, the turnaround from loss to profit for the six months ended 30 June 2021 was mainly due to a combination of factors as follows:—

- (i) the Group recorded a 36% overall increase in terms of income for the six months ended 30 June 2021 as compared with the corresponding period in 2020, due to significant increase in domestic orders which resulted in an increase in gross profit of approximately HK\$17 million;

- (ii) the fair value gain of financial assets at fair value through profit or loss of approximately HK\$48 million for the six months ended 30 June 2021 as compared with the corresponding period of approximately HK\$10 million in 2020; and
- (iii) the reversal of expected credit loss on a loan receivable (which was formerly a convertible bonds receivable before 25 March 2021) of approximately HK\$25 million for the six months ended 30 June 2021 as compared with the corresponding period in 2020 which was nil.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2021. The information contained in this announcement is only based on the unaudited management accounts of the Group and information currently available to the Group, which is subject to finalisation and necessary adjustments and has not been confirmed, or reviewed by the auditors of the Company. Details of the financial results of the Group will be disclosed in the Group's interim results announcement for the six months ended 30 June 2021 which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the financial results announcement carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Kaisa Health Group Holdings Limited
Zhang Huagang
Chairman

Hong Kong, 17 August 2021

As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman), and Mr. Kwok Ying Shing, and Ms. Kwok Ho Lai and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping, and Ms. Li Yonglan.